By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 

Company News
Peptidream Achieves Milestone For Initiation Of Clinical Development For Bristol-Myers Squibb (BMY)’s First Collaboration Product Candidate 6/15/2016 8:20:52 AM
New Data On Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) Indicate Benefit In Heavily Pre-Treated Classical Hodgkin Lymphoma Patients In Phase II, Single-Arm Pivotal Trial 6/10/2016 8:39:25 AM
Bristol-Myers Squibb (BMY) To Announce Results For Second Quarter 2016 On July 28 6/9/2016 10:53:40 AM
Bristol-Myers Squibb (BMY) Announces Dividend 6/8/2016 10:42:45 AM
Bristol-Myers Squibb (BMY) Announces New Rheumatoid Arthritis Research And Real-World Data At The Annual European Congress Of Rheumatology (EULAR 2016) 6/8/2016 8:18:14 AM
Bristol-Myers Squibb (BMY) And MD Anderson Cancer Center Announce New Research Collaboration In Immuno-Oncology Focused On Lung Cancer 6/7/2016 10:52:32 AM
ASCO2016: Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) And Yervoy (Ipilimumab) Combination Regimen Shows Clinically Meaningful Responses In First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase Ib Study Checkmate -012 6/6/2016 1:56:20 PM
ASCO2016: Bristol-Myers Squibb (BMY) Release: First Presentation Of Phase II Checkmate -142 Study Evaluating Opdivo (Nivolumab) Alone Or In Combination With Yervoy (Ipilimumab) Demonstrates Encouraging Clinical Activity In MSI-High Metastatic Colorectal Cancer 6/6/2016 1:35:22 PM
ASCO2016: Bristol-Myers Squibb (BMY) Promising Response Rates With Opdivo® (Nivolumab) Observed In Advanced Form Of Bladder Cancer From Phase I/II Study Checkmate -032 6/6/2016 1:17:37 PM
Long-Term Data From Two Trials Evaluating The Opdivo (Nivolumab) And Yervoy (Ipilimumab) Regimen In Advanced Melanoma Continues To Validate Bristol-Myers Squibb (BMY)’s Immuno-Oncology Combination Approach 6/6/2016 11:54:07 AM